ABVX
ABIVAX
Stock Euronext / Paris – Stock Market Prices, News & Analysis
Abivax focuses its efforts on the discovery and development of treatments for viral and inflammatory diseases.
ABIVAX
ABVX
Abivax focuses its efforts on the discovery and development of treatments for viral and inflammatory diseases.
Anantys Community
Anantys Community
1 member holds ABIVAX with an average return of -9.6%. Join them to follow signals and build your long-term investment strategy.
Price history of ABIVAX
Price history of ABIVAX
Performance & Momentum
Abivax rocked by AstraZeneca buyout rumors despite denial
At the end of March 2026, Abivax shares reacted to speculation about an exclusivity period granted to AstraZeneca for a possible takeover bid. However, Abivax's official denial cooled enthusiasm, maintaining volatility in the stock amid ongoing rumors that have persisted for months.
Strategic Analysis
ABIVAX • 2026
Abivax positions itself as an innovative player in biotechnology, focused on the research and development of treatments for serious viral and inflammatory diseases. Its specialization in therapeutic niches with high medical need provides a differentiating advantage despite a fragile financial context.
Strengths
- Targeted portfolio focused on conditions with high medical potential
- Innovation capacity through advanced biotechnology research
- Track record of spectacular long-term performance
Weaknesses
- Dependence on clinical phases and regulatory validation
- Vulnerability to market rumors, as illustrated by the recent decline in speculation about a potential acquisition
Momentum
The momentum remains strong, supported by significant investor interest in the medium to long term. However, it has recently been tempered by the dilution of hopes related to a potential acquisition operation. This suggests that the current dynamic will require a return to tangible clinical advancements to maintain its momentum.
Similar stocks to ABIVAX
Recent News
ABIVAX
Abivax falls as buyout hopes fade
2 months agoSince the start of 2026, Abivax has dropped over 17%, with the recent decline continuing this trend after the likelihood of a buyout by Eli Lilly diminished. Despite this pullback, the stock remains in focus following a stellar performance last year. The daily decline, slightly above 1%, reflects market caution in response to the news.
Abivax Draws Big Pharma Interest on Promising Data
3 months agoIn December 2025, Abivax caught market attention amid speculation of a potential buyout, fueled by highly encouraging advanced clinical results in an inflammatory bowel disease. This momentum boosted the stock price, reflecting strong interest from major pharmaceutical companies in the French biotech. Despite a recent moderate drop of 1.2%, the overall trend remains positive, supported by this favorable backdrop.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
